Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

This study has been completed.
Information provided by (Responsible Party):
Vascular Biogenics Ltd. operating as VBL Therapeutics Identifier:
First received: July 8, 2010
Last updated: November 15, 2011
Last verified: November 2011
The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.

Condition Intervention Phase
Drug: VB-201 or Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers

Further study details as provided by Vascular Biogenics Ltd. operating as VBL Therapeutics:

Estimated Enrollment: 320
Study Start Date: October 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Multiple doses of VB-201 Drug: VB-201 or Placebo
Placebo Comparator: Placebo Drug: VB-201 or Placebo


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients, ≥18 to ≤75 years of age;

Exclusion Criteria:

  • Presence of, or history of cancer, with the exception of completely excised, non-metastatic squamous cell or basal cell carcinomas of the skin;
  • Has a clinically significant systemic infection (e.g., chronic or acute infection, UTI, URI) within 30 days of Day 0, or a history or presence of recurrent or chronic infection (e.g. viral infections, [including hepatitis B or C, HIV], bacterial infections, systemic fungal infections, or syphilis);
  • Subjects with a history of coronary events within the last 6 months;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01159730

United Kingdom
VBL Investigative Site
Glasgow, Scotland, United Kingdom
Sponsors and Collaborators
Vascular Biogenics Ltd. operating as VBL Therapeutics
  More Information

Responsible Party: Vascular Biogenics Ltd. operating as VBL Therapeutics Identifier: NCT01159730     History of Changes
Other Study ID Numbers: VB-201-030
Study First Received: July 8, 2010
Last Updated: November 15, 2011 processed this record on May 24, 2017